Rhythm Biosciences secures first Southeast Asian distribution deal for geneType platform
Rhythm Biosciences (ASX: RHY) has executed a distribution agreement with Digistain Limited, marking the company’s first formal commercial entry into Southeast Asia. The 12-month agreement, commencing 3 March 2026, grants Digistain rights to market and distribute Rhythm’s geneType genetic testing platform initially in the Philippines, with provisions to expand across the region. The arrangement provides structured revenue visibility through per-test pricing and monthly volume commitments, creating a capital-efficient pathway into a large, underserved market without requiring Rhythm to build regional infrastructure.
Digistain, a UK-based cancer diagnostics distributor with established Southeast Asian networks, brings existing commercial infrastructure including a sub-distribution relationship with Precision Healthcare PTE. The partnership allows Rhythm to leverage Digistain’s regional footprint rather than deploying significant capital to establish its own presence.
Join thousands of readers who start here
Our best articles, sent straight to your inbox. You can unsubscribe anytime.
Why Southeast Asia matters for genetic risk testing
Southeast Asia represents a compelling growth opportunity for advanced genetic diagnostics. The region’s large population base, increasing healthcare expenditure and improving access to private healthcare create favourable conditions for testing platforms like geneType. Current penetration of advanced genetic diagnostics remains relatively low across the region, positioning validated, cost-effective solutions for strong adoption potential.
Genetic risk testing uses DNA analysis to identify individuals at elevated risk of developing certain conditions, enabling earlier intervention and monitoring. The geneType platform provides clinically validated risk assessment across nine tests spanning cancer predisposition and cardio-metabolic risk. Testing is conducted at Rhythm’s NATA-accredited laboratory and partner facility AGRF in Melbourne, ensuring international quality standards.
The platform’s multi-disease assessment capabilities cover breast cancer, cardiovascular disease, diabetes, colorectal cancer, prostate cancer and melanoma. Tests are delivered through healthcare providers and genetic counsellors, providing appropriate clinical oversight for patients receiving results.
How the distribution model works
The commercial structure provides clear operational parameters while maintaining flexibility for regional expansion.
| Term | Detail | Significance |
|---|---|---|
| Initial term | 12 months from 3 March 2026 | Allows market testing before larger commitment |
| Pricing | Agreed per-test transfer price | Clear revenue per sample processed |
| Volume commitment | Monthly minimum volumes | Provides baseline commercial floor |
| Exclusivity | Non-exclusive | Rhythm retains flexibility to add other regional partners |
Revenue is generated per test as samples are processed and reported, with 30-day payment terms and monthly invoicing. The agreement includes a six-week turnaround from sample receipt to clinical report delivery, consistent with Rhythm’s existing service standards. No upfront payments or capital commitments are required from either party.
The per-test revenue model means cash generation scales directly with adoption. Non-exclusive arrangements preserve Rhythm’s ability to engage additional distribution partners across the broader Southeast Asian region as opportunities develop.
Partnership brings established regional infrastructure
Digistain Limited, headquartered in Newport Pagnell, England, distributes cancer diagnostic products across multiple international markets. The company has established commercial distribution networks across Asia, Scandinavia and Latin America, with existing sub-distribution infrastructure in Southeast Asia through its relationship with Precision Healthcare PTE.
This infrastructure reduces Rhythm’s execution risk by providing immediate access to established channels rather than requiring the company to build regional teams or deploy capital for market entry. The agreement is governed by the laws of Victoria, Australia, with structured dispute resolution provisions including escalation, mediation and arbitration.
David Atkins, Managing Director and CEO
“This agreement represents a meaningful step in translating our geneType platform into commercial test volumes. Southeast Asia is a region where we see genuine long-term opportunity for genetic risk testing and partnering with an established international distributor such as Digistain gives us a structured and capital-efficient pathway into these markets. We see this as the beginning of a scalable regional opportunity.”
The Territory is defined as the Philippines and other markets as agreed by the parties, reflecting the shared intention to use the initial launch market as a foundation for broader Southeast Asian expansion.
Next steps and timeline
Rhythm and Digistain will progress the operational onboarding phase of the agreement through several immediate steps:
- Training of Digistain personnel on geneType platform capabilities and protocols
- Finalisation of sample logistics protocols for Southeast Asian markets
- Co-development of marketing materials tailored to regional requirements
- Commencement of commercial activity following completion of onboarding
- Progressive activation of additional markets within the Territory by mutual agreement
The company has not provided specific revenue guidance given the early-stage nature of the initial Territory launch and inherent uncertainty in forecasting adoption rates in a new market. Near-term catalysts include commencement of commercial activity and potential announcements of additional markets being added to the Territory.
Enjoyed this article?
We publish high-impact stories like this a few times a week. No spam.
What this means for Rhythm’s growth strategy
The Digistain agreement validates Rhythm’s dual-platform strategy. The geneType platform was acquired as part of Rhythm’s approach to early cancer detection, operating alongside the company’s ColoSTAT blood-based test for colorectal cancer. ColoSTAT, based on research from Australia’s CSIRO and protected by international patents, measures five specific protein biomarkers indicating the likelihood of colorectal cancer in symptomatic individuals.
The geneType platform’s design emphasises broad international applicability, with testing infrastructure already established through Rhythm’s NATA-accredited laboratory facilities in Melbourne. This Southeast Asian entry demonstrates the company can monetise geneType through partnership models while ColoSTAT progresses toward commercialisation, diversifying revenue pathways.
The commercial significance of the Digistain agreement extends beyond immediate financial impact. It establishes a strategic platform for Southeast Asian market entry and provides a foundation for growth in geneType test volumes as Digistain’s regional distribution network activates. The structured pricing framework and volume commitments provide baseline expected activity during the initial 12-month term, with potential upside as additional markets come online.
For investors, this represents the first contracted distribution channel in Southeast Asia for Rhythm Biosciences, creating a scalable regional opportunity without significant capital deployment. The agreement demonstrates commercial traction for the geneType platform in international markets characterised by large underserved populations and rising healthcare expenditure.
Want the Next Biotech Deal in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements drop.